Spots Global Cancer Trial Database for spartalizumab
Every month we try and update this database with for spartalizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | NCT04028245 | Carcinoma, Rena... | Spartalizumab Canakinumab | 18 Years - 99 Years | Columbia University | |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | NCT04310397 | Pathologic Stag... Pathologic Stag... Pathologic Stag... | Dabrafenib Spartalizumab Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | NCT04294160 | BRAF V600 Color... | Dabrafenib LTT462 Trametinib LXH254 TNO155 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | NCT04191421 | Metastatic Panc... Stage IV Pancre... | Siltuximab Spartalizumab | 18 Years - | Emory University | |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis | |
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) | NCT04736485 | Gastric Cancer ... Resectable Carc... | perioperative t... | 18 Years - | Centre Francois Baclesse | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | NCT03647488 | Carcinoma, Non-... | Capmatinib Spartalizumab Docetaxel | 18 Years - | Novartis | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | NCT05201066 | Myelodysplastic... Leukemia, Myelo... | decitabine spartalizumab sabatolimab azacitidine venetoclax INQOVI (oral de... | 12 Years - 99 Years | Novartis | |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma | NCT05135845 | Oesophageal Ade... Gastric Adenoca... | Capmatinib Spartalizumab | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | NCT04323436 | Carcinoma, Non-... | Spartalizumab Capmatinib spartalizumab p... | 18 Years - | Novartis | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
